Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xilio TherapeuticsXLO +0.52%32 3-Year EBITDA Growth Rate is 52.30% as of Jun. 2026, which is 159% above its 10-year median of 20.20. GuruFocus rates XLO with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Xilio Therapeutics ranks better than 87.13% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 52.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 37.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Xilio Therapeutics was 56.50% per year. The lowest was -65.40% per year. And the median was 20.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Xilio Therapeutics 3-Year EBITDA Growth Rate Related Terms
XLO vs INKT, IMA, HRTX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Xilio Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xilio Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xilio Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Xilio Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 52.30% mean?
Xilio Therapeutics (XLO) has a 3-Year EBITDA Growth Rate of 52.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Xilio Therapeutics and its competitors. This is 159% above median its historical median of 20.20. According to the industry distribution chart, Xilio Therapeutics ranks #145 out of 1127 companies in the Biotechnology industry, placing it in the top 12.9%.
Is Xilio Therapeutics' 3-Year EBITDA Growth Rate too high?
Xilio Therapeutics' current 3-Year EBITDA Growth Rate of 52.30% is 159% above median its 10-year median of 20.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Xilio Therapeutics' value of 52.30% is 258.2% above this industry median. Based on the distribution chart, Xilio Therapeutics ranks #145 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xilio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Xilio Therapeutics' 3-Year EBITDA Growth Rate compare to INKT and IMA?
According to the Biotechnology industry distribution chart, Xilio Therapeutics ranks #145 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Xilio Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. Xilio Therapeutics' value of 52.30% is 258.2% above this benchmark. While the company's 10-year median is 20.20 vs. the industry median of 14.60, Xilio Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xilio Therapeutics's current 3-Year EBITDA Growth Rate of 52.30% is 258.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Xilio Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xilio Therapeutics's current 3-Year EBITDA Growth Rate is 52.30%, which is 159% above median its own 10-year median of 20.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xilio Therapeutics stock overvalued right now?
Xilio Therapeutics (XLO) has a current 3-Year EBITDA Growth Rate of 52.30%. The current 3-Year EBITDA Growth Rate is 52.30%, which is 159% above median its 10-year median of 20.20 and 258.2% above the Biotechnology industry median of 14.60. Xilio Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Xilio Therapeutics (XLO), the current 3-Year EBITDA Growth Rate is 52.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
32GF Score
Get the complete analysis for XLO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XLO has been successfully added to your 
